Datapoint: Opdivo Becomes First Immunotherapy Approved to Treat Gastric Cancer

The FDA on April 16 approved Bristol Myers Squibb’s blockbuster cancer drug Opdivo as a first-line treatment for gastric cancer, gastroesophageal junction cancer and advanced or spreading esophageal adenocarcinoma. The PD-1 inhibitor is the first immunotherapy approved to treat gastric cancer. Opdivo was first approved to treat advanced melanoma in December 2014. In that indication, the drug holds covered or better status for 52% of all insured lives.

SOURCE: MMIT Analytics, as of 4/21/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 20

Datapoint: FDA Expands Otezla’s Psoriasis Label

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today